WO1999016450A1 - Budesonid zur behandlung von cholestatischen lebererkrankungen - Google Patents
Budesonid zur behandlung von cholestatischen lebererkrankungen Download PDFInfo
- Publication number
- WO1999016450A1 WO1999016450A1 PCT/EP1998/005568 EP9805568W WO9916450A1 WO 1999016450 A1 WO1999016450 A1 WO 1999016450A1 EP 9805568 W EP9805568 W EP 9805568W WO 9916450 A1 WO9916450 A1 WO 9916450A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- budesonide
- treatment
- cholestatic liver
- liver diseases
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the present invention relates to the use of the known drug budesonide for the treatment of certain liver diseases.
- non-cholestatic liver diseases therapy with immunosuppressants, including corticosteroids such as prednisolone or budesonide, has been established (Dar ⁇ ielsson et al., Aliment. Pharmacol. Ther., 1994, 8, 585-590).
- immunosuppressants including corticosteroids such as prednisolone or budesonide
- PBC primary biliary cirrhosis
- PSC primary sclerosing cholangitis
- AC autoimmune cholangitis
- Budesonide is a steroid that is 52% to 79% absorbed in the intestine within four to six hours. Its affinity for corticoid receptors is 15 times greater than that of prednisolone. The first-pass metabolism by the liver is 80% to 90%. The systemic bioavailability is around 10%. Due to these properties, budesonide is one of the steroids with extremely low side effects, but the high first-pass metabolism and the low systemic bioavailability of budesonide seem to rule out treatment of cholestatic liver diseases.
- Ursodeoxycholic acid in combination with prednisolone or budesonide in the therapy of primary biliary cirrhosis In: Bile acids in Hepatobiliary Diseases: Basic Research and Clinical Application. Pp. 299-302. Kluwer Academic Publishers, Dordrecht, 1997. The use of budesonide alone and not as a support for ursodeoxycholic acid was not considered promising and was therefore not proposed in the prior art. Despite the good treatment successes in the treatment of cholestatic liver diseases with ursodeoxycholic acid, there is a need for further drugs which achieve similarly good results in the treatment of cholestatic liver diseases.
- the object of the invention is therefore to provide a medicament which can successfully treat cholestatic liver diseases, in particular primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune cholangitis.
- budesonide for the treatment of cholestatic liver diseases, in particular for the treatment of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune cholangitis, is therefore made available.
- budesonide is not administered to support the treatment of cholestatic liver disease with ursodeoxycholic acid, but rather represents the actual active ingredient for the treatment of the diseases are therefore not the subject of the invention.
- the budesonide can be formulated in a manner known per se into medicaments for mammals, preferably humans.
- Budesonide is present in the medicinal products in a mixture with a pharmaceutical organic or inorganic carrier which is suitable for enteral or parenteral administration.
- Oral administration of the invention Drugs over tablets, capsules, powder or in liquid form such as a suspension, in solution, as an emulsion or as a syrup are particularly preferred.
- customary pharmaceutical carriers such as lactose, microcrystalline cellulose, starch and anhydrous silica, lubricants such as hydrogenated castor oil, magnesium stearate, sodium lauryl sulfate and talc, and binders such as starch, glucose, gum arabic and mannitol are used.
- compositions according to the invention are to be administered via liquids
- customary liquid carriers can be used.
- the additives corn starch, lactose, Aerosil, polyvinylpyrrolidone and magnesium stearate are preferably used.
- corn starch, lactose, magnesium stearate and Aerosil are preferably used as additives.
- compositions according to the invention can likewise be formulated in a manner known per se as depot formulations or to medicaments with delayed or sustained release.
- the daily doses of budesonide to be administered are preferably about 0.5 mg to 100 mg per day, depending on the severity of the disease, the patient's condition, other existing diseases, the route of administration and other parameters which are routinely taken into account by the treating doctor the daily doses are 1 mg to 50 mg and particularly preferably 5 mg to 20 mg.
- the daily doses can be administered all at once or at different times, for example three times a day.
- the above-mentioned daily doses contain the formulations according to the invention preferably 0.5 mg to 10 mg, particularly preferably 1 mg to 5 mg budesonide per unit dosage form.
- Formulation example 1 tablets of 5 m ⁇
- the moist mass is passed through a 1 mm sieve and dried. After sieving the dried mass again
- Formulation example 2 capsules of 3 m ⁇
- the solution is dropped into 1000 ml of water (pH 3.5, citrate buffer, 50 mM) with strong shearing with an Ultraturrax.
- the resulting solution is filled into 1 ml ampoules and sterilized at 121 ° C for 20 minutes.
- GPT alanine aminotransferase
- AP alkaline phosphatase
- LAP leucine aminopeptidase
- Another parameter of one Cholestatic liver disease indicates the serum activity of the LAP.
- An increased level of enzyme activity in the serum indicates a hepatobiliary disease with obstructive and nonobstructive cholestasis.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT98947504T ATE236640T1 (de) | 1997-09-26 | 1998-09-02 | Budesonid zur behandlung von cholestatischen lebererkrankungen |
DE59807874T DE59807874D1 (de) | 1997-09-26 | 1998-09-02 | Budesonid zur behandlung von cholestatischen lebererkrankungen |
DK98947504T DK0966289T3 (da) | 1997-09-26 | 1998-09-02 | Budesonid til behandling af cholestatiske leversygdomme |
IL12990098A IL129900A (en) | 1997-09-26 | 1998-09-02 | Use of budesonide for the preparation of a pharmaceutical composition for the treatment of cholestatic liver diseases |
EP98947504A EP0966289B1 (de) | 1997-09-26 | 1998-09-02 | Budesonid zur behandlung von cholestatischen lebererkrankungen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19742612.3 | 1997-09-26 | ||
DE19742612A DE19742612A1 (de) | 1997-09-26 | 1997-09-26 | Budesonid zur Behandlung von cholestatischen Lebererkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999016450A1 true WO1999016450A1 (de) | 1999-04-08 |
Family
ID=7843772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/005568 WO1999016450A1 (de) | 1997-09-26 | 1998-09-02 | Budesonid zur behandlung von cholestatischen lebererkrankungen |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0966289B1 (de) |
AT (1) | ATE236640T1 (de) |
DE (2) | DE19742612A1 (de) |
DK (1) | DK0966289T3 (de) |
ES (1) | ES2191340T3 (de) |
IL (1) | IL129900A (de) |
PT (1) | PT966289E (de) |
WO (1) | WO1999016450A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD2852C2 (ro) * | 2005-03-28 | 2006-04-30 | Георге АНГЕЛИЧ | Utilizarea budesonidei pentru tratamentul ascitei rezistente la pacienţii cu ciroză hepatică |
-
1997
- 1997-09-26 DE DE19742612A patent/DE19742612A1/de not_active Withdrawn
-
1998
- 1998-09-02 AT AT98947504T patent/ATE236640T1/de active
- 1998-09-02 WO PCT/EP1998/005568 patent/WO1999016450A1/de active IP Right Grant
- 1998-09-02 PT PT98947504T patent/PT966289E/pt unknown
- 1998-09-02 IL IL12990098A patent/IL129900A/en not_active IP Right Cessation
- 1998-09-02 ES ES98947504T patent/ES2191340T3/es not_active Expired - Lifetime
- 1998-09-02 DE DE59807874T patent/DE59807874D1/de not_active Expired - Lifetime
- 1998-09-02 EP EP98947504A patent/EP0966289B1/de not_active Expired - Lifetime
- 1998-09-02 DK DK98947504T patent/DK0966289T3/da active
Non-Patent Citations (8)
Also Published As
Publication number | Publication date |
---|---|
IL129900A (en) | 2002-11-10 |
DK0966289T3 (da) | 2003-07-07 |
DE59807874D1 (de) | 2003-05-15 |
EP0966289B1 (de) | 2003-04-09 |
ES2191340T3 (es) | 2003-09-01 |
EP0966289A1 (de) | 1999-12-29 |
PT966289E (pt) | 2003-08-29 |
ATE236640T1 (de) | 2003-04-15 |
DE19742612A1 (de) | 1999-04-01 |
IL129900A0 (en) | 2000-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1011682B1 (de) | Mittel zur hormonalen kontrazeption | |
EP0310541B1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Geburtseinleitung und zum Schwangerschaftsabbruch sowie zur Behandlung gynäkologischer Störungen | |
DE4429398C2 (de) | Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption | |
DE60309895T2 (de) | Estrogenersatztherapie | |
DE4308406C1 (de) | Kombinationspräparat zur Kontrazeption | |
DE69125714T2 (de) | Zusammensetzung für die behandlung des humanen prostata adenokarzinom | |
DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
WO1998035682A1 (de) | Mittel zur hormonalen kontrazeption und/oder behandlung und/oder prophylaxe von tumoren der brustdrüsen mit drei hormonkomponente | |
EP0723439A1 (de) | Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen | |
DE29717252U1 (de) | Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen | |
DE102005034498A1 (de) | Orale Kontrazeption mit Trimegeston | |
EP1100509B1 (de) | Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie | |
US20100016264A1 (en) | Treatment for dry eye using testosterone and progestagen | |
DE69721314T2 (de) | Hormonzusammensetzung welche ein östrogenes mittel und ein progestatives mittel enthält | |
EP0787002B1 (de) | Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle | |
DE4229820A1 (de) | Pharmazeutische Zubereitung auf Gestagen-Basis | |
EP1761242A2 (de) | Filmförmiges, oral zu verabreichendes arzneimittel, enthaltend estriol | |
DE69724796T2 (de) | Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten | |
DE2206570B2 (de) | Verwendung von ( + ) - Catechin | |
EP0966289B1 (de) | Budesonid zur behandlung von cholestatischen lebererkrankungen | |
DE69827017T2 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung | |
DD238921A5 (de) | Verfahren zur herstellung einer kontrazeptiven synergistischen zusammensetzung | |
WO2000024388A2 (de) | Kombinationsmittel zur behandlung entzünglicher darmerkrankungen von 5-aminosalicylsäure und einem von budenosid, 6-methylprednisolon oder prednisolon | |
EP1886694B1 (de) | Perorale Arzneiform mit Dienogest und Ethinylestradiol zur Kontrazeption | |
DE102006003508A1 (de) | Arzneimittel umfassend eine Hormonkombination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 129900 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): IL |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998947504 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1998947504 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998947504 Country of ref document: EP |